2018 Corporate Excellence Awards Supplement

140 CORPORATE VISION / Corporate Excellence Awards 2018 32 CORPORATE VISION / Issue 7 2018 , SimpsonHealthcare Executives, founded by Kelly Simpson-Angelini, CEO& CSO, is a diverse scientific agency. We caught up with Danielle Gallagher to discover more about the firmwho are currently celebrating their 20th year of business. Committed to the Healthcare Experience and Scientific Innovation Established in 1998, Simpson Healthcare is a diverse scientific agency currently celebrating its 20th year of business. In an ever- evolving healthcare landscape, Kelly believes that providing great branded and disease education to physicians is essential to advancing the story of science that their clients need to tell. Brands of the future must be more personalised and precise as the firm prioritises the overarching goal of healthcare: helping people live better. Shaping brand behaviour and ensuring positive brand experiences for patients, requires healthcare teams to tap into their innovative potential to uncover what healthcare consumers really want and to deliver that. There have been many scientific, diagnostic, and therapeutic innovations over the past two decades that have led healthcare teams to achieve great health outcomes for their patients, and the therapeutic advancements in development will continue to improve how diseases are managed into the future at a rapid pace. The team at Simpson Healthcare anticipate that they will have a better and earlier diagnosis of disease in many therapeutic areas, as well as a better management of disease due to better physician education and our increasing level of connectivity. Their founder understands that there will be great opportunities in the near future to work on novel therapies, such as once-in-a-lifetime gene therapies that could improve quality of life for patients in a significant way. In addition to this, they look forward into the future as they aim to best support the brands of tomorrow and to prepare their clients to have the greatest and most positive impact for patients. For the past 20 years, the firm have had the opportunity to work with heritage biopharmaceutical clients including: Pfizer, Shire, AstraZeneca, Genzyme, Merck, to name a few, having focused 1806CV11 our innovations on supporting them in the development of new therapies. The scientific expertise and disruptive thinking methods among members of their organisation span across a broad array of many major disease categories, including respiratory, oncology, cardiovascular, immunology, rare diseases, gastrointestinal, adult vaccines, and severe asthma. The firm’s medical and strategy teams are catalysts of industry innovation as they bring to bear the larger context of healthcare for their clients, aligned in their purpose and always keeping the patient at the centre of their focus. Discussing the steps Simpson Healthcare take when undertaking a new project to ensure that clients receive the best possible outcome, Danielle explains to us the process the team abides by. “Here at Simpson Healthcare, we pull through the story of why our clients’ therapeutic brands matter for patients and how they will improve their lives. We dig deeper into the science of the therapies that our clients are developing and what it means for patients who could benefit the most from their therapy. At the start of a new project, our internal team will align with our client on strategic vision, project management details, and the long-term value that will be added to the healthcare industry throughout the entire therapeutic brand lifecycle. After working with our client to clearly define the problem or opportunity, we will then outline our objectives and timelines and move forward in a collaborative path. “Also, we ensure that we have the right members on our teams and think disruptively about the delivery of our story to our audience, which means that we pull through the experiences of our organisation with previous similar challenges. We believe that everyone on our team should know our client’s goals and how our scientific story will support it using a wide array of